Kaléo to pay out more than $12M in false claims case regarding high-priced version of cheap opioid overdose antidote; UroGen gets ready to start PhIII cancer trial
Virginia pharma Kaléo has agreed to pay the United States $12.7 million to resolve accusations that the pharma caused the submission of false claims for Evzio, an injectable form of naloxone hydrochloride indicated for use to reverse opioid overdose.
Evzio was the highest-priced version of naloxone on the market, and insurers had required the submission of prior authorization requests before they would approve covering Evzio.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.